Search for a trial

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

To assess the feasibility of administering DCBI after CRS-HIPEC in patients with malignant peritoneal mesothelioma.